Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC

This study is testing whether adding a drug called anlotinib to standard chemotherapy (pemetrexed and carboplatin) improves outcomes for people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic mutation (EGFR) and has stopped responding to a drug called osimertinib. **You may be eligible if...** - You are between 18 and 75 years old - You have locally advanced or metastatic non-squamous NSCLC confirmed by tissue biopsy - Your cancer has the EGFR mutation and has progressed (worsened) on osimertinib - Your tumor can be measured on imaging - Your life expectancy is at least 3 months and overall health is good - Your blood counts and organ function (kidney, liver) are within acceptable levels **You may NOT be eligible if...** - You have small cell lung cancer or mixed adenosquamous lung cancer - You have active brain metastases (cancer that has spread to the brain and is not controlled) - Uncontrolled high blood pressure - You have serious heart disease or clotting/bleeding problems - You have had major surgery in the past 4 weeks or a major infection - You are pregnant or breastfeeding - You have had significant recent bleeding (coughing up blood) Talk to your doctor to see if this trial is right for you.